2-furan-2-yl-N5-[1-(5-methyl-isoxazol-3-ylmethyl)-piperidin-4-yl]-[1,2,4]triazolo[1,5-a][1,3,5]triazine-5,7-diamine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 三嗪类
• 英文名称: 2-furan-2-yl-N5-[1-(5-methyl-isoxazol-3-ylmethyl)-piperidin-4-yl]-[1,2,4]triazolo[1,5-a][1,3,5]triazine-5,7-diamine
• 英文别名: 2-(furan-2-yl)-5-N-[1-[(5-methyl-1,2-oxazol-3-yl)methyl]piperidin-4-yl]-[1,2,4]triazolo[1,5-a][1,3,5]triazine-5,7-diamine
• 化学式: C₁₈H₂₁N₉O₂
• 分子量: 395.424
• InChiKey: ACTNRWABPDYOKF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  29
• 可旋转键数：
  5
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.39
• 拓扑面积：
  136
• 氢给体数：
  2
• 氢受体数：
  10

反应信息

• 作为产物：
  描述：

  3-羟甲基-5-甲基异恶唑 在 三乙胺 作用下， 以 二氯甲烷 、 乙腈 为溶剂， 反应 18.0h， 生成 2-furan-2-yl-N5-[1-(5-methyl-isoxazol-3-ylmethyl)-piperidin-4-yl]-[1,2,4]triazolo[1,5-a][1,3,5]triazine-5,7-diamine
  参考文献：
  名称：

  Novel Diamino Derivatives of [1,2,4]Triazolo[1,5-a][1,3,5]triazine as Potent and Selective Adenosine A_2a Receptor Antagonists

  摘要：

  Piperazine derivatives of 2-furanyl[1,2,4]triazolo[1,5-a][1,3,5]triazine have recently been demonstrated to be potent and selective adenosine A(2a) receptor antagonists with oral activity in rodent models of Parkinson's disease. We have replaced the piperazinyl group with a variety of linear, monocyclic, and bicyclic diamines. Of these diamines, (R)-2-(aminomethyl)pyrrolidine is a particularly potent and selective replacement for the piperazinyl group. With this diamine component, we have been able to prepare numerous analogues with low nanomolar affinity toward the A(2a) receptor and good selectivity with respect to the A(1) receptor (> 200-fold in some cases). Selected analogues from this series of [1,2,4]triazolo[1,5-a][1,3,5]triazine have now been shown to be orally active in the mouse catalepsy model.

  DOI：

  10.1021/jm0498396

文献信息

• Triazolotriazines and pyrazolotriazines and methods of making and using the same
  申请人：Vu Chi

  公开号：US20060276475A1

  公开（公告）日：2006-12-07

  The invention is based on the discovery that compounds of formula (I) possess unexpectedly high affinity for the A 2a adenosine receptor, and can be useful as antagonists thereof for preventing and/or treating numerous diseases, including Parkinson's disease. In one embodiment, the invention features a compound of formula I: (I)

  该发明基于发现，化合物(I)的公式具有意外的高亲和力，可用作拮抗剂，用于预防和/或治疗许多疾病，包括帕金森病的A2a腺苷受体。在一种实施例中，该发明涉及公式I的化合物：(I)。
• EP1615930A2
  申请人：——

  公开号：EP1615930A2

  公开（公告）日：2006-01-18
• US7285550B2
  申请人：——

  公开号：US7285550B2

  公开（公告）日：2007-10-23
• [EN] TRIAZOLOTRIAZINES AND PYRAZOLOTRIAZINES AND METHODS OF MAKING AND USING THE SAME<br/>[FR] TRIAZOLOTRIAZINES ET PYRAZOLOTRIAZINES ET LEURS PROCEDES DE FABRICATION ET D'UTILISATION
  申请人：BIOGEN IDEC INC

  公开号：WO2004092170A2

  公开（公告）日：2004-10-28

  The invention is based on the discovery that compounds of formula (I) possess unexpectedly high affinity for the A2a adenosine receptor, and can be useful as antagonists thereof for preventing and/or treating numerous diseases, including Parkinson’s disease. In one embodiment, the invention features a compound of formula I: (I)